title: [5 years of dosage intensification and autologous bone marrow or peripheral stem cell transfusion in malignant lymphoma with a high risk of recurrence].
abstract: Clinical results of the treatment of malignant lymphomas with a high risk of relapse by dose intensification and autologous bone marrow transplantation are reported. Since 1988, 68 patients with a median age of 34 years (range 16 to 56 years) received dose intensification, including 25 non-Hodgkin's lymphomas in first remission (12 lymphoblastic or Burkitt's lymphomas and 13 large cell lymphomas with risk factors), 20 aggressive non-Hodgkin's lymphomas in chemosensitive relapse, and 23 Hodgkin's lymphomas in chemosensitive relapse. The calculated 3-year overall survival and relapse-free survival was 72% (CI: 57-82%) and 61% (CI: 47-73%) respectively. Treatment related deaths were seen in 4.4%. The median duration of hospitalization was 30 days (range 19-51 days). The relapse-free 3-year survival for the separate treatment groups was 80% for lymphoblastic and Burkitt's lymphomas in first remission, 77% for large cell lymphomas with clinical risk factors in first remission, 39% for aggressive non-Hodgkin's lymphomas in chemosensitive relapse, and 59% for Hodgkin's lymphomas in chemosensitive relapse. These excellent results were obtained with acceptable toxicity and justify the use of dose intensification for a group of young patients with high risk lymphomas.
authors.affiliation: Abteilung für Onkologie, Universitätsspital Zürich.
authors.forename: L M
authors.initials: LM
authors.lastname: Jost
authors.forename: G
authors.initials: G
authors.lastname: Pichert
authors.forename: M
authors.initials: M
authors.lastname: Reichlin
authors.forename: E
authors.initials: E
authors.lastname: Müller
authors.forename: E
authors.initials: E
authors.lastname: Jacky
authors.forename: H P
authors.initials: HP
authors.lastname: Honegger
authors.forename: J
authors.initials: J
authors.lastname: Gmür
authors.forename: R A
authors.initials: RA
authors.lastname: Stahel
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D002051:Burkitt Lymphoma / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D016019:Survival Analysis
vernacular_title: Fünf Jahre Dosisintensivierung mit Rücktransfusion autologer Knochenmarksoder peripherer Stammzellen bei malignen Lymphomen mit hohem Rezidivrisiko.